Assessment of Dietary Balance in Home-Dwelling Patients With Stage 4 and 5 Chronic Kidney Disease Using URIKI (IKI), a Connected Urine Test Strip and In Vitro Diagnostic Medical Device

NCT07746037 | Not Yet Recruiting

• 2 other identifiers: APHP2605332026-A00977-44
• Study Type: interventional
• Target: 450
• Locations: 1 country
• Sites: 2

Brief Summary

The goal of this clinical trial is to evaluate whether the integration of URIKI, a connected urine test strip and in vitro diagnostic medical device, can improve the nutritional management of patients with stage 4 or 5 chronic kidney disease (CKD) living at home. The primary purpose is to assess whether URIKI can support dietary monitoring and optimize dietitians' workload through remote collection of urinary and nutrition-related data. The main question it aims to answer is: Does the integration of URIKI improve the efficiency of dietitians' work in the nutritional follow-up of patients with stage 4 or 5 chronic kidney disease? Participants will: Receive a URIKI kit at home, including a portable reader, urine test strips, and access to the My URIKI mobile application. Perform one urine measurement per day at home for 10 consecutive days using the URIKI device. Enter nutrition- and health-related information into the application, including meal photographs or descriptions, hydration information, and responses to brief questionnaires. Receive remote support for installation and use of the device if needed. Have their urinary measurements reviewed by authorized healthcare professionals. Receive a personalized dietary assessment and nutritional feedback from the hospital medical team and/or IKI dietitians through the My URIKI application. Complete patient experience questionnaires at study entry and at the end of participation. The expected duration of participation is up to 30 days. Approximately 450 patients with stage 4 or 5 chronic kidney disease will be enrolled in nephrology centers across France.

Conditions

Chronic Kidney Disease (CKD)

Outcome Measures

Primary Outcomes (1)

• Before-after mean duration of dietitian consultations

  Difference in the mean duration of dietitian consultations dedicated to nutritional assessment per patient, comparing the pre-intervention period (conventional care) and the post-intervention period (care integrating URIKI).

  Outcome compared between the 6-month pre-implementation and 6-month post-implementation periods of URIKI system

Secondary Outcomes (7)

• Carbon footprint of the care pathway

  Up to 12 months

• Renal outcome

  Up to 12 months

• Biological outcome

  Up to 12 months

• Patient satisfaction

  Around Day 30 following URIKI use

• Patient engagement

  Around Day 30 following URIKI use

Study Arms (1)

single arm

EXPERIMENTAL

This is a single-arm, before-and-after interventional study evaluating the implementation of URIKI within the nutritional care pathway of patients with stage 4 or 5 chronic kidney disease in routine clinical practice. Participants receive standard nephrology and dietetic care supplemented by the URIKI system, which includes connected urine test strips, a portable reader, the My URIKI mobile application, and a healthcare professional platform. Participants perform daily home urine measurements for 10 days and provide nutrition- and hydration-related information through the application. Outcomes collected after URIKI implementation are compared with data from a 6 months pre-intervention period representing conventional care without URIKI.

Device: URIKI Digital Urinary Monitoring System

Interventions

URIKI Digital Urinary Monitoring System DEVICE

URIKI is a digital in vitro diagnostic system designed to support nutritional assessment in patients with stage 4 or 5 chronic kidney disease. The intervention includes connected urine test strips, a portable reader, the My URIKI mobile application, and a secure healthcare professional platform. Participants perform urine measurements at home once daily for 10 consecutive days and enter nutrition- and hydration-related information into the application, including meal information and patient-reported outcomes. Urinary biomarker results and patient-reported data are transmitted to authorized healthcare professionals and used to support nutritional assessment and personalized dietary follow-up. The intervention is delivered in addition to routine nephrology and dietetic care and is evaluated as part of the implementation of URIKI within the chronic kidney disease nutritional care pathway.

Also known as: My URIKI

single arm

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Adults aged 18 years or older.
• Chronic kidney disease (CKD) stage 4 or 5 with estimated glomerular filtration rate (eGFR) \<30 mL/min/1.73 m².
• Followed in a nephrology department within a structured care pathway that includes nutritional assessment.
• Clinical indication or need for nutritional assessment as part of routine care.
• Willing and able to use the URIKI device for nutritional assessment.
• Able to understand French or English, or assisted by a caregiver capable of supporting device use and understanding study procedures.
• Agreement to the use of the device and to the collection and transmission of study-related data.
• Affiliation with a social security system or beneficiary of such coverage.
• Access to a compatible smartphone, a smartphone provided by IKI, or assistance from a caregiver for use of the mobile application

You may not qualify if:

• Pregnant or breastfeeding women.
• Severe cognitive impairment preventing understanding of study procedures or use of the application without caregiver assistance.
• Major motor or sensory impairments (e.g., blindness, hemiplegia) preventing use of the device without caregiver assistance.
• Inability to understand French or English without support from a caregiver or third party.
• Refusal of the loaned smartphone or persistent inability to use the provided equipment despite support.
• Refusal to participate in the study or withdrawal after receiving study information.
• Individuals under legal protection (guardianship or curatorship), unless participation is authorized by the legal representative and ethics committee

Sponsors & Collaborators

• Assistance Publique - Hôpitaux de Paris: lead
• SKEZI, IKI, DALI: collaborator

Study Sites (2)

Hôpital Pitié-Salpêtrière - APHP, Département de Néphrologie, Néphrologie Ambulatoire et Onco-Néphrologie

Paris, France

Location

Hôpital Tenon - APHP, Département de Néphrologie, Néphrologie Ambulatoire et Onco-Néphrologie

Paris, France

Location

MeSH Terms

Conditions

Renal Insufficiency, Chronic

Condition Hierarchy (Ancestors)

Renal Insufficiency; Kidney Diseases; Urologic Diseases; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Male Urogenital Diseases; Chronic Disease; Disease Attributes; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Study Officials

• Corinne Isnard Bagnis

  Assistance Publique - Hôpitaux de Paris

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Youcef Sekour

CONTACT

+33156095823; youcef.sekour@aphp.fr

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: HEALTH SERVICES RESEARCH
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: July 27, 2026
• First Posted: August 4, 2026
• Study Start (Estimated): October 1, 2026
• Primary Completion (Estimated): November 1, 2027
• Study Completion (Estimated): November 1, 2027
• Last Updated: August 4, 2026

Record last verified: 2026-08

Data Sharing

• IPD Sharing: Will share
• Shared Documents: STUDY PROTOCOL, ICF
• Time Frame: Two years after the last publication
• Access Criteria: Data sharing must be accepted by the sponsor and the PI based on a scientific project and scientific involvement of the PI team. Collaboration will be fostered. The founder could be involved in the decision. Teams wishing obtain IPD must meet the sponsor and IP team to present scientifics (and commercial) purpose, IPD needed, format of data transmission, and timeframe. Technical feasibility and financial support will be discussed before mandatory contractualization. Processing of shared data must comply with European General Data Protection Regulation (GDPR).

Locations

FR (2)